Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes

Analysis of claims data showed reduced utilization and costs among patients with nonintensively treated type 2 diabetes (T2D) using self-monitoring of blood glucose compared with continuous glucose monitoring.

Related Keywords

Switzerland ,Italy ,Bari ,Puglia ,United States ,Rotkreuz ,Switzerland General ,Netherlands ,American ,Eli Lilly ,Santa Clara ,Santa Barbara ,David Kerr ,Diabetes Technology Society ,Department Of Precision ,Medtronic ,Novo Nordisk ,American Diabetes Association ,Us Bureau Of Labor Statistics ,Astrazeneca ,Roche Diagnostics International Ltd ,Health Care ,American Diabetes Association Standards Of Care ,Coalition For Clinical Research ,D International Classification Of Diseases ,Santa Barbara Actuaries Inc ,Study Group ,University Of Bari Aldo Moro ,American Diabetes Association Professional Practice Committee ,Boehringer Ingelheim ,European Association For The Study Of Diabetes ,Novartis ,Merative Marketscan Commercial ,International Classification ,Tenth Revision ,Clinical Modification ,Charlson Comorbidity Index ,Consumer Price ,American Diabetes Association Standards ,Roche Diabetes Care ,Roche Molecular Systems ,Regenerative Medicine ,Ionian Area ,Internal Medicine ,Metabolic Diseases ,Bari Aldo Moro ,Roche Diabetes ,European Association ,Roche Diagnostics ,Merck Sharp ,Diabetes Association Professional Practice ,Clinical Research Self Monitoring ,Blood Glucose Scientific ,Diabetes Sci ,Res Clin ,Medical Care ,Accessed November ,Diabetes ,Blood Glucose ,Cgm ,T2d ,